Global Transdermal Drug Delivery Market to 2020: Strategic Analysis, Technologies, Competitor Profiles, Financial Evaluation, Product Pipeline Assessment and Swot Investigation

  • ID: 3095362
  • SWOT Analysis
  • Region: Global
  • 280 pages
  • Kelly Scientific Publications
1 of 6


  • 3M
  • Ascend Therapeutics
  • Endo International
  • Janssen Pharmaceuticals
  • Novartis
  • ProStrakan
  • MORE
This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 320 tables & figures over 280 pages. This report is presented as follows:

- By Geography (Global, USA)
- By Parent Market (Drug Delivery Systems, Advanced Drug Delivery Systems)
- By Sub-market (Generics, Women’s Health, Analgesics, Neuropathic Pain)

A wealth of financial data & business strategy information is provided including:

- Up-to-date company financials, sales & revenue figures
- Revenue and market forecasts
- Business model strategies for drug delivery, pharmaceutical and biotechnology companies
- Comprehensive account of company products, financials & portfolios

SWOT, Economic & Regulatory Environment specifics include:

- Key strengths, weaknesses and threats influencing leading player position within the market
- Technologies driving the market (e.g., chemical enhancers, microneedles)
- Top fastest growing market segments and emerging opportunities
- Top pharmaceutical companies within the market
- Comprehensive product portfolios, R&D activity and pipeline products
- M&A activity and future strategies of top companies
- High demand and unmet need enhances the market
- Challenges of the transdermal drug delivery market

Who should read this report?
- Pharmaceutical, biotechnology and diagnostic companies with an interest in personalized medicine
- Industry professionals and business strategists will discover key information to propel their policies
- Investors will gain inside information to dominant players in the industry and future forecasts
- Scientists will get a business perspective and industry insight into how scientific breakthroughs influence the market environment

C-Suite professionals, Decision Makers, Business Development professionals

This report will tell you if the companies mentioned are:
- Strong, competitive players
- Pooling their resources for specific growth and therapeutic areas
- Investing strategically in R&D
- Have a history of strategic M&A activity

This detailed report is supported with 320 figures and tables over 280 pages and profiles the main pharmacos in the transdermal drug delivery market.
Note: Product cover images may vary from those shown
2 of 6


  • 3M
  • Ascend Therapeutics
  • Endo International
  • Janssen Pharmaceuticals
  • Novartis
  • ProStrakan
  • MORE
1.0 Executive Summary
1.1 Objectives of Report
1.2 Data Sources & Methodology
1.3 Key Findings & Observations
1.3.1 The Global Drug Delivery Market has a Growth Rate of 5%
1.3.2 The Transdermal Drug Delivery Market is Growing Vertically
1.3.3 Who are the Leading Players in the Market?
1.3.4 Neurodegenerative Disorders Such as Alzheimer’s and Parkinson’s Disease Will Propel the Future Market
1.3.5 Why is the Transdermal Drug Delivery Market so Promising?
1.3.6 What are the Main Drivers of the Market?
1.3.7 First, Second and Third Generation Drug Delivery Systems
1.3.8 The Niche Market of Commercially Available Skin Models
1.3.9 Transdermal Drug Delivery Technologies are Providing the Market with Niche Spaces
1.3.10 Nanotechnology is Transforming Transdermal Drug Delivery
1.3.11 Can Transdermal Drug Delivery be Applied to Cancer Vaccination?
1.3.12 Gene Therapy Advancement Using Transdermal Delivery

2.0 Transdermal Drug Delivery
2.1 Introduction
2.2 Developments of Transdermal Drug Delivery to Date
2.3 The Skin – Anatomy and Physiology
2.3.1 Drug Administration via the Intracellular Pathway
2.3.2 Drug Administration via the Intercellular Pathway
2.3.3 Fick’s Law
2.4 Factors that Influence Transdermal Drug Delivery
2.4.1 Parameters Influencing Skin Permeability The Vehicle Drug Concentration Partition Coefficient
2.5 Strategies to Enhance Transdermal Drug Delivery
2.5.1 1st Generation Delivery Systems
2.5.2 2nd Generation Delivery Systems
2.5.3 Chemical Enhancers
2.5.4 3rd Generation Delivery Systems
2.6 Comparison of Transdermal Delivery with Other Methods
2.7 Advantages of Transdermal Drug Delivery
2.7.1 First-Pass Metabolism
2.8 Disadvantages of Transdermal Delivery
2.9 Complications of Transdermal Therapy
2.9.1 Overdose
2.9.2 Skin Sensitivity and Reactions
2.9.3 MRI-Induced Skin Burns

3.0 Biomechanical and Pharmacological Elements Effecting Transdermal Drug Delivery
3.1 Factors That Influence Transdermal Drug Delivery
3.1.1 Rate of Permeation Across the Skin
3.1.2 Skin Characteristics
3.1.3 Drug Characteristics
3.1.4 pH and Pharmacokinetics
3.2 Transdermal Drug Design
3.2.1 Factors That Affect the Absorption of the Drug Hydration and Temperature Biotransformation of the Drug in the Skin
3.2.2 Selecting Drug and Vehicle
3.2.3 Drug Modification Ion-Pair Formation Drug Complexation
3.2.4 Thermodynamic Activity of the Drug within the Vehicle Eutectic Systems Vehicle Formulation Modification of the Stratum Corneum
3.3.1 Static Franz Diffusion Cell
3.4 Commercially Available Skin Models for Transdermal Drug Testing
3.5 In vivo Testing of Transdermal Drug Delivery Systems
3.5.1 In vivo Testing of Drug Delivery Systems
3.5.2 Modelling of Transport Through the Skin

4.0 Transdermal Drug Delivery Technologies
4.1 Introduction
4.1.1 Local Application Formulations
4.1.2 Liquid Crystals for Transdermal Drug Delivery
4.1.3 Microemulsions for Transdermal Drug Delivery
4.1.4 Nanoemulsions for Transdermal Drug Delivery
4.1.5 Transdermal Gel Technology
4.1.6 Biphasix System
4.1.7 Penetration Enhancers
4.1.8 Chemical Enhancers
4.1.9 Nitric Oxide-Based Transdermal Drug Delivery
4.2 Vesicular transdermal carriers
4.2.1 Liposomes
4.2.2 Transfersomes
4.2.3 Ethosomes
4.2.4 Elastic Vesicles
4.3 Transdermal Patch
4.3.1 Types of Transdermal Patch
4.3.1a Single-layer Drug-in-Adhesive
4.3.1b Multi-layer Drug-in-Adhesive
4.3.1c Reservoir
4.3.1d Matrix Patch
4.3.1e Vapour Patch
4.3.1 Transdermal Patches Adhesives
4.3.2 New Technologies
4.3.3 h-Patch™ Controlled Release Micropump System
4.4 Patchless Transdermal Delivery System
4.5 Metered-Dose Transdermal System
4.6 Polymers for Transdermal Drug Delivery
4.6.2 Film Forming Polymeric Solutions
4.7 Physical Methods to Promote Transdermal Delivery
4.7.1 Electrotransport
4.7.2 Electroporation Drug delivery by Electroporation Electrochemotherapy
4.7.3 Cryoelectrophoresis
4.7.4 Iontophoresis Application of Iontophoresis for Drug Delivery Companies with Technologies for Drug Delivery by Iontophoresis
4.8 How Combining Electrophoresis and Iontophoresis Impacts Drug Delivery
4.9 Dermaportation
4.9.1 Radiofrequency-Driven Transdermal Delivery
4.9.2 Transcutaneous Drug Delivery by Electropulsation
4.9.3 Skin Patch Systems and Electrostatic Force
4.9.4 Heat-Aided Drug Delivery
4.9.5 Ultrasound
4.9.6 Magnetophoresis
4.10 Use of Lasers for Transdermal Drug Delivery
4.10.1 Laser-Induced Microporation
4.10.2 Painless Laser Injection
4.10.3 Laser-Induced Pressure Waves Transdermal Drug Delivery by Laser-Assisted Changes in Skin
4.11 How Pressurized Gas is Transforming Transdermal Drug Delivery
4.12 Microscission Induced by Gas
4.13 Role of Microelectromechanical Systems (MEMS) in Transdermal Drug Delivery
4.14 Microneedles and Dermal Microinjection
4.15 Microneedle Arrays for Drug Delivery
4.15.1 Microneedle Patch
4.15.2 Applications of Microneedles
4.15.3 AdminPatch® Microneedle Array
4.15.4 Dissolving Microneedles
4.16 Biodegradable Microneedles
4.17 Ceramic Microneedle Arrays
4.18 Dissolvable Microneedle Patches
4.18.1 MicorCor
4.18.2 MicroPyramid™
4.19 Microstructured Transdermal Systems
4.20 Microneedle Transdermal Chip
4.21 Microneedle Applicator Device
4.22 DebioJect ™ Microneedle Technology
4.23 Silk Microneedles
4.24 Tattooing
4.25 ZP Patch Microprojections Technology
4.26 Other Microneedle Products Currently Available
4.27 Needlefree injections
4.28 Glide SDI® Solid Dose Injector
4.29 Jet Injection
4.29.1 Why is Needle-Free so Important?
4.29.2 Mini-Ject Needlefree Delivery System
4.29.3 PharmaJet Stratis
4.29.4 MicroJet for Painless Injections
4.29.5 Nanoliter-Volume Pulsed Microjets
4.30 SUMAVEL™ DosePro™ Needle-Less Injection
4.31 Skin Abrasion

5.0 How Nanotechnology is Transforming Transdermal Drug Delivery
5.1 Overview
5.2 Nanotechnology-Based Transdermal Drug Delivery
5.2.1 Nanobiotechnology for Transdermal Application
5.3 Nanoparticles and Nanoemulsions for Skin Disorders
5.4 Nanopatches
5.4.1 Vaxxas Nanopatch Technology
5.4.2 Effect of Mechanical Flexion on Penetration of Bucky Amino Acids Through the Skin
5.5 Inocyte™ Epidermal Drug Delivery System
5.6 Ionic Nanoparticle Technology
5.7 Solid Lipid Nanoparticles (SLN) Gels
5.8 siRNA- Nanoparticle Conjugates
5.9 Transdermal Nanoparticle Preparations for Systemic Effect
5.10 Micellar Nanoparticle Estradiol Emulsion (MNPEE)
5.11 Transferosomes
5.12 Nanocarriers
5.13 Nanotechnology for Vaccination and Immunotherapy
5.14 Safety Issues of Applications of Nanomaterial Carriers on the Skin
5.15 Comparison of Current Transdermal Drug Delivery Systems

6.0 Transdermal Drug Delivery and Disease States
6.1 Antiaging Products
6.2 Cancer
6.2.1 d-Amino Levulinic Acid
6.2.2 Breast Cancer & Afimoxifene Gel
6.2.3 Cervical Cancer & Interferon a2b
6.2.4 Prostate Cancer & Nitroglycerine
6.2.5 Prostate Cancer & Estradiol Gel
6.2.6 Prostate Cancer & Leuprolide Acetate
6.2.7 Skin Cancer & Caffeine
6.2.6 Cancer Vaccines Intradermal Delivery Using Adenoviral Vectors Peptide Cancer Vaccines Electroporation of Anticancer Agents
6.3 Cardiovascular Disease
6.3.1 Transdermal Anticoagulants
6.3.2 Angina Pectoris
6.3.3 Atherosclerotic Cardiovascular Disease Transdermal Oestrogen for Prevention of Atherosclerotic Cardiovascular Disease
6.3.4 Congestive Heart Failure
6.3.5 Hypertension Clonidine ß-Blockers Calcium Channel Blockers
6.4 Chronic Fatigue Syndrome
6.5 Contraception
6.5.1 Female Contraception Agile Therapeutics AG200-15 BAY86-5016 / FC Patch Low BAY86-5016 Desogestrel Ortho Evra™
6.5.2 Male Contraception Transdermal Progestin Plus Testosterone
6.6 Diabetes
6.6.1 Insulin Drug Delivery V-Go GLP1 Agonist
6.7 Men’s Health
6.7.1 Benign Prostatic Hypertrophy Tamsulosin Transdermal Drug Delivery System
6.7.2 Erectile Dysfunction Topical and Transdermal Preparation for Erectile Dysfunction
6.7.3 Hypogonadism Topical Testosterone
6.8 Musculoskeletal Disease
6.8.1 Osteoarthritis
6.8.2 Osteoporosis Alendronate Estrogen Human Parathyroid Hormone
6.9 Nausea and Vomiting
6.9.1 Chemotherapy-Induced
6.9.2 Motion Sickness
6.9.3 Postoperative Vomiting
6.10 Neurological Disease
6.10.1 Alzheimer's Disease Arecoline Rivastigmine Donepezil
6.11 Attention Deficit Hyperactivity Disorder
6.11.1 Methylphenidate
6.12 Bipolar Disorder
6.12.1 Lithium
6.13 Depression
6.13.1 Antidepressants
6.13.2 Selective Serotonin-Reuptake Inhibitors
6.13.3 Fluoxetine
6.13.4 Monoamine Oxidase Inhibitors
6.13.5 Selegiline
6.13.6 Trazodone Hydrochloride
6.13.7 Venlafaxine
6.13.8 Bupropion
6.14 Epilepsy
6.15 Migraine
6.15.1 Sumatriptan
6.15.2 Zolmitriptan
6.16 Parkinson's Disease
6.16.1 Introduction
6.16.2 Dopamine Agonists Levodopa Rotigotine
6.16.3 Other Agents
6.17 Restless Leg Syndrome
6.17.1 Rotigotine
6.18 Schizophrenia
6.18.1 Haloperidol
6.18.2 Risperidone
6.18.3 Blonanserin
6.19 Tinnitus/Vertigo
6.22.1 Nicotine
6.20 Tourette syndrome
6.21 Multiple Sclerosis
6.22 Respiratory diseases
6.22.1 Asthma and Chronic Obstructive Pulmonary Disease (COPD)
6.23 Skin disorders
6.23.1 Cutaneous Leishmaniasis
6.23.2 Hair Loss
6.23.3 Iontophoretic Drug Delivery for Nail Disorders
6.23.4 Psoriasis Nanoemulsions for Paxitacel in Psoriasis Iontophoresis for Treatment of Psoriasis
6.24 Overactive Bladder and Urinary Incontinence
6.24.1 Oxybutynin
6.25 Pain
6.25.1 Chronic Pain
6.25.2 Transdermal Local Anesthetics
6.25.3 Transdermal Fentanyl for the Management of Postoperative Pain
6.25.4 Fibromyalgia
6.25.5 Minor Medical Procedures
6.25.6 Neuralgia Lidoderm
6.25.7 Nonsteroidal Anti-Inflammatory Drugs Topical NSAIDs
6.25.8 Ketoprofen
6.25.9 Opioids
6.25.10 Cancer Pain Fentanyl Nitroglycerine Buprenorphine
6.26 Smoking Cessation
6.26.1 Nicotine Replacement Therapy
6.26.2 Nicotine Patch in Pregnancy
6.27 Viral infections
6.27.1 Transdermal Nanoparticles for Immune Enhancement in HIV
6.28 Women's Health
6.28.1 Dysmenorrhea
6.28.2 Female Infertility
6.28.3 Female Sexual Arousal Disorder
6.28.4 Menopause Hormone Replacement Therapy Estradiol Parathyroid Hormone for Postmenopausal Osteoporosis Testosterone and Low Libido
6.29 Transdermal Nutraceuticals

7.0 Gene Therapy and Transdermal Drug Delivery
7.1 Overview
7.2 Plasmid DNA and Electroporation
7.2.1 TriGrid™ Delivery System
7.2.3 Magnetic Pulse Electroporation
7.3 Antisense Therapy

8.0 Vaccines and Transdermal Drug Technology
8.1 Introduction
8.1.1 The Skin as an Immune Organ Langerhans Cells- Epidermal Antigen Presenting Cells Keratinocytes- Immune Competent Epithelial cells Dendritic Epidermal T Cells (DETC) ?d T cells -Specialised Resident Epithelial Cells Epidermotropic T lymphocytes-Circulating T Cells that home to the Epidermis Melanocytes-Epidermal Pigment Cells With Immune Properties
8.2 Current Technologies
8.2.1 Dissolvable Microneedle Array
8.2.2 Electroporation for Administering DNA Vaccines
8.2.3 Microneedles for Transdermal Vaccine Delivery
8.2.4 Needle-Free Delivery of Vaccines
8.3 Applications for Transdermal Vaccination
8.3.1 HIV/AIDS Vaccine
8.3.2 Transdermal DNA Influenza Vaccine
8.3.3 Transdermal Aß Vaccine for Alzheimer’s Disease
8.3.4 Transdermal Vaccine for Traveller’s Diarrhoea

9.0 Global Drug Delivery Market
9.1 Overview and Analysis
9.2 USA Drug Delivery Market
9.3 European Drug Delivery Market
9.4 Emerging Drug Delivery Markets
9.5 The Advanced Drug Delivery Landscape
9.6 Transdermal Drug Delivery Market
9.7 Smoking Cessation Drug Market
9.7.1 Nicotine Replacement Therapeutics
9.7.2 Non-Nicotine Containing Therapeutics
9.7.3 Smoking Cessation Products in the Pipeline
9.8 Neurodegenerative Disorders Such as Alzheimer’s & Parkinson’s disease will Propel the Future Market
9.9 How Transdermal Systems Relate to the Global Pain Market
9.9.1 Neuropathic Pain Market (US, UK, France, Germany, Japan, Spain and Italy) 2014-2020
9.9.2 Transdermal Products Within the Neuropathic Pain Market
9.10 How Transdermal Systems Relate Within the Generic Market
9.11 Duragesic and Generic Fentanyl Transdermal System Competition
9.12 Lidocaine Market Analysis
9.13 Who are the Leading Players in the Market?
9.14 What is Driving the Transdermal Drug Delivery Market?
9.15 Increased Number of Geriatric and Pediatric Patients is Propelling the Market
9.16 Unmet Needs Within the Transdermal Drug Delivery Market
9.17 Women’s Health Market

10.0 Transdermal Drug Delivery Company Business Profiles and Strategic Evaluation
10.1 Actavis
10.2 Actelion
10.3 GlaxoSmithKline
10.4 Bayer
10.5 Mylan Pharmaceuticals
10.6 Novartis
10.7 Upsher-Smith
10.8 Ascend Therapeutics
10.9 AMAG Pharmaceuticals (Lumara Health, KV Pharma/Ther-Rx Corp)
10.10 Janssen Pharmaceuticals
10.11 Noven Pharmaceuticals
10.12 ProStrakan
10.13 Shire
10.14 Hercon Pharmaceutical
10.15 Kremers Urban Pharmaceuticals
10.16 Nitto Denko
10.17 Teva Pharmaceutical Industries
10.18 Endo International
10.19 Teikoku USA
10.20 Boehringer Ingelheim
10.21 3M
10.22 UCB
10.23 ParPharm

11.0 Transdermal Drug Delivery Company Financial Analysis
11.1 Actavis
11.2 Actelion
11.3 GlaxoSmithKline
11.3.1 ViiV Healthcare
11.4 Bayer
11.5 Janssen Pharmaceuticals (Johnson & Johnson)
11.6 Shire
11.7 Nitto Dento
11.8 Teva Pharmaceuticals
11.9 Endo International
11.10 Boehringer Ingelheim
11.11 3M
11.12 UCB
11.13 ParPharm

12.0 Current Transdermal Drug Delivery Products on the Market
12.1 Actavis
12.1.1 Androderm
12.1.2 Fentanyl Transdermal System
12.1.3 Lidocaine Topical Patch
12.1.4 Oxytrol
12.2 Actelion
12.2.1 Vachlor Gel (mechlorethamine)
12.3 GlaxoSmithKline
12.3.1 Niquitin/Nicoderm
12.4 Bayer
12.5 Mylan Pharmaceuticals
12.5.1 Clonidine Transdermal System
12.5.2 EMSAM (Selegiline Transdermal System)
12.5.3 Estradiol Transdermal System
12.5.4 Fentanyl Transdermal System
12.5.5 Nitroglycerin Transdermal System
12.5.6 XULANE (Norelgestromin / Ethinyl Estradiol Transdermal System)
12.6 Novartis
12.6.1 Exelon Patch (Rivastigmine Transdermal System)
12.6.2 Duragesic - Fentanyl Patches
12.6.3 Transderm Scop - Scopolamine Patches
12.7 Upsher-Smith
12.7.1 Vogelxo – Testosterone (1%) Gel
12.8 ASCEND Therapeutics
12.8.1 EstroGel®
12.9 AMAG Pharmaceuticals (Lumara Health)
12.9.1 Evamist®
12.10.1 OrthoEvra®
12.10.2 Duragesic®
12.11 Lavipharm
12.11.1 Fentadur
12.11.2 Nicotine Transdermal Patch
12.11.3 Acne Transdermal Patch
12.11.4 Trinipatch
12.12 Noven Pharmaceuticals
12.12.1 Minivelle®
12.12.2 CombiPatch®
12.12.3 Daytrana®
12.13 ProStraken
12.13.1 Sancuso®
12.14 Shire
12.14.1 Daytrana® CII
12.15 Hercon Pharmaceuticals
12.15.1 Nitroglycerin Transdermal System
12.16 Kremers Urban Pharmaceuticals
12.16.1 Nitroglycerin Transdermal System
12.17 Nitto Dento
12.17.1 Bisono Tape
12.17.2 Penles Tape
12.17.3 Passport Advanced Drug Delivery System
12.18 Teva Pharmaceuticals
12.18.1 Zecuity
12.18.2 Transdermal Fentanyl (generic)
12.18.3 Tev Tropin
12.19 Endo International
12.19.1 Lidoderm®Patch
12.19.2 Fortesa Gel
12.20 Teikoku
12.20.1 Lidoderm® 1
12.20.2 IontoPatch®
12.21 3M
12.21.1 3M Fentanyl Transdermal Delivery System
12.21.2 3M Rivastigmine Transdermal Delivery System
12.21.3 Microneedles
12.22 UCB
12.22.1 Neupro®
12.23 ParPharm
12.23.1 Fentanyl Transdermal System

13.0 In-Depth SWOT Analysis of the Transdermal Drug Delivery Market
13.1 Drivers of the Market
13.1.1 Patent Expirations and Introduction of Generics
13.1.2 Increased Patient Compliance Rates
13.1.3 Increased Rate of Chronic Conditions and Application of Patch Technology to These Areas
13.1.4 Increased Geriatric and Pediatric Drug Administration Requirements
13.2 Restraints and Weaknesses of the Transdermal Drug Delivery Market
13.2.1 Technical Restraints
13.2.2 Drug Adverse Reactions
13.2.3 Drug Failures
13.3 Opportunities Within the Market Place
13.3.1 High number of Pharmaco & Drug Delivery Company Collaboration
13.3.2 Increasing Indications and Disease States for Transdermal Administration
13.3.3 Large Opportunity for Home Health Care Market and OTC
13.3.4 Targeted Drug Delivery
13.4 Barriers to Market Entry

Appendix 1: Further Reading & Bibliography

List of Tables
Table 2.1 Currently Approved Transdermal Drug Delivery Systems by Indication & Type
Table 2.2: Transdermal Products for Local Tissue Treatment Currently on the US Market
Table 2.3 Chemical Enhancers for Transdermal Delivery Systems
Table 2.4: Third Generation Drug Delivery Systems, Mechanism, Commercial Names, Company Name and Active Ingredient
Table 2.5: Advantages of Transdermal Drug Delivery
Table 2.6 Skin Irritation and Sensitization Associated with Transdermal Delivery Systems
Table 3.1 Commercially Available Skin Models for Transdermal Drug Testing
Table 3.2: Methods to Assess Drug Penetration into and/or Across the Skin
Table 4.1: Advantages and Disadvantages of Micro-Emulsions
Table 4.2: Comparison of Microemulsion with Conventional Emulsion
Table 4.3 Overview of Transdermal Drug Delivery Systems Containing Microemulsions
Table 4.4. Commercial Nanoemulsion Formulation
Table 4.5 Advantages and Disadvantages of using Nanoemulsions for Transdermal Drug Delivery
Table 4.6 Transdermal Gel Types
Table 4.7 Advantages and Disadvantages of Transdermal Gels
Table 4.8 Enhancer Mechanisms of Action
Table 4.9 Typical Transfersome Composition
Table 4.10 Use of Transferosomes in Transdermal Drug Delivery
Table 4.11 Use of Ethosomes in Transdermal Drug Delivery
Table 4.12 Research Studies using Invasomes
Table 4.13 Other Elastic Vesicles as drug carriers
Table 4.14 Pressure Sensitive Adhesives
Table 4.15 Properties of Pressure Sensitive Adhesives
Table 4.16 Patchless Transdermal Drugs
Table 4.17 Use of Polymers in Transdermal Drug Delivery Systems
Table 4.18 Topical Delivery of Drugs and Macromolecules Into the Skin Using Electroporation
Table 4.19 Clinical Trial Data of Patient outcomes using Electrochemotherapy
Table 4.20 Factors that Affect the Efficacy of Iontophoresis
Table 4.21 Applications of Transdermal Iontophoretic Drug Delivery
Table 4.22 Iontophoretic Devices on the Market
Table 4.23 Iontophoretic Products in Development
Table 4.24 Drug Delivery via Radiofrequency-Driven Transdermal Delivery
Table 4.25 Ways in Which Ultrasound can Enhance Drug Delivery
Table 4.26 Types of Microneedles
Table 4.27 Properties of Microneedles
Table 4.28 Applications of Microneedles
Table 4.29 Comparison of Solid and Hollow Microstructured Transdermal Systems
Table 4.30 Advantages and Disadvantages of Needlefree Injections
Table 4.31 Needlefree Injectors on the Market
Table 5.1 Nanocarriers Frequently used in Transdermal Drug Delivery Systems
Table 5.2 Applications of Nanocarriers in Transdermal Drug Delivery
Table 5.3 Summary of the Nanocarrier Applications in Transdermal Drug Delivery
Table 5.4 Nanoparticles and Nanoemulsions for Skin Disorders
Table 5.5 Potential Uses of Solid Lipid Nanoparticles (SLN) Formulations
Table 5.6 Nanotechnology-Based Transdermal Vaccination and Immunotherapy
Table 6.1Transdermal Anti-Aging Products
Table 6.2: Cardiovascular Disease Subtypes
Table 6.3 Commercially Available Nitroglycerine Patches
Table 6.4. Potential Transdermal Treatments for Congestive Heart Failure
Table 6.5 Transdermal Drug Delivery Systems for Antihypertensive Drugs
Table 6.6 Research Advances in Systemic Deli very of ß-blockers via Skin
Table 6.7: Calcium Channel Blockers with High Potential for use in Transdermal Delivery
Table 6.8 Research Advances in Systemic Delivery of Calcium Channel Blockers via Skin
Table 6.9 Agile Therapeutics Pipeline Transdermal Contraceptives
Table 6.10: Main Treatment Profiles of Benign Prostate Hypertrophy
Table 6.11 Advantages of Tamsulosin Transdermal Drug Delivery System
Table 6.12 Treatments for Erectile Dysfunction
Table 6.13 Hypogonadism Primary-Originating from a Problem in the Testicles
Table 6.14 Hypogonadism Secondary-Problem with the Pituitary or Hypothalamus-Testicles are Normal
Table 6.15 Commercially Available Topical Testosterone Formulations
Table 6.16 Osteoporosis Risk Factors
Table 6.17 Hormone and Bisphosphonate Therapy to Treat Osteoarthritis
Table 6.18 Research Findings on Transdermal Administration of Alendronate
Table 6.19 Major Types and Causes of Epilepsy
Table 6.20: NeuroDerm’s Levodopa/Carbidopa Candidate Product Portfolio for Parkinson’s Disease
Table 6.21 Potential Transdermal Drug Treatments for Pain
Table 6.22 Local Topical Anesthetics by Generic Name and Pharmaokinetic Profiles
Table 6.23 Possible Transdermal Therapies in the Treatment of Fibromyalgia
Table 6.24 Commercially Available Topical Anaesthetics
Table 6.25 Topical Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Table 6.26 Transdermal Opioids in Current Research
Table 6.27 Transdermal Duragesic Patch Doses Available
Table 6.28 Non-Transdermal Methods for Nicotine Replacement
Table 6.29 Non-nicotine Replacement and Anti-Smoking Treatments with Potential for Transdermal Drug Delivery
Table 6.30 Common Causes of Female Infertility
Table 6.31 Transdermal Therapies Currently Under Development for the Treatment of Female Sexual Arousal Disorder
Table 7.1 Modification of the Nucleic Acid Strand for more Effective Transdermal Delivery
Table 7.2: Transdermal Delivery Methods of Antisense in Research
Table 8.1 Advantages and Disadvantages of Dissolvable Microneedles
Table 8.2 Vaccines and Model Antigens used in Microneedle-based Vaccine Delivery Trials
Table 9.1: Main Sub-Markets of the Global Drug Delivery Market
Table 9.2: Global Drug Delivery System Historical Market ($ Billions) and CAGR 2010-2014
Table 9.3: Global Drug Delivery System Market Forecast ($ Billions) and CAGR 2014-2020
Table 9.4: Factors Providing Momentum to The US Drug Delivery Market
Table 9.5: USA Drug Delivery System Market Historical Figures 2010-2014
Table 9.6: USA Drug Delivery System Market Forecast 2014-2020
Table 9.7: Europe Drug Delivery Market Historic Worth 2010-2014
Table 9.8: Europe Drug Delivery Market Forecast 2014-2020
Table 9.9: Main Pharmaco Players in Europe
Table 9.10: Factors Propelling the Asian Drug Delivery Market
Table 9.11: Top Selling Indications for Transdermal Delivery Patch Systems
Table 9.12: Top Indications and Active Ingredients Used Within the Transdermal Drug Delivery Market
Table 9.13: Top Seven Transdermal Drug Products By Sales
Table 9.14: Market Changing Smoking Cessation Products in Development Stage
Table 9.15: Top Ten Most-Prescribed Drugs in the U.S., 2011
Table 9.16: Neuropathic Pain Market Worth (US, UK, France, Germany, Japan, Spain and Italy) 2010-2014
Table 9.17: Neuropathic Pain Market Worth (US, UK, France, Germany, Japan, Spain and Italy) 2014-2020
Table 9.18: Current Top Therapeutics within the Neuropathic Pain Market
Table 9.19: Global Generics Market Value 2012-2018
Table 9.20: Top Ten Generic Manufacturer Companies
Table 9.21: Vulnerable Branded Transdermal Patch Systems Once Patent Protection Expires
Table 9.22: Main Competitors in the Duragesic Generic Fentanyl Transdermal System Market
Table 9.23: Key Players in the Transdermal Drug Delivery Market
Table 9.24: Factors Driving the Transdermal Drug Delivery Market
Table 9.25: Top Women’s Health Brands by USA Sales
Table 10.1 Actavis Structure
Table 10.2 Actavis Key Facts and Figures
Table 10.3 Business Acquisitions
Table 10.4 Actavis Business Development Profile
Table 10.5 Recent Actavis Disposals
Table 10.6 Actelion Pulmonary Arterial Hypertension Franchise
Table 10.7: Actelion Speciality Transdermal/Oral Products
Table 10.8: Actelion Therapeutic Pipeline Products
Table 10.9: GlaxoSmithKline Overview 2013
Table 10.10: GlaxoSmithKline Objectives and Strategic Business Plan
Table 10.11:Bayer Therapeutic Areas of Interest
Table 10.12: Bayer Important Drug Candidates Currently Submitted for Approval
Table 10.13: Bayer Important Agents in R&D Development Stages and Clinical Phases
Table 10.14: Therapeutic Portfolio of Mylan Pharmaceuticals
Table 10.15: Top Transdermal drug Delivery Products: Novartis
Table 10.16: Upsher-Smith Therapeutic Areas of Interest
Table 10.17: Upsher-Smith Key Branded Products (Women’s Health, Generics, Consumer)
Table 10.18: Upsher-Smith Key Generic Products
Table 10.19: Lumara Health’s Product Portfolio
Table 10.20: Janssen Pharmaceuticals Therapeutic Areas of Interest
Table 10.21: Johnson & Johnson Pharmaceutical Division Therapeutic Areas of Interest
Table 10.22: Lavipharm Pharmaceutical Division Therapeutic Areas of Interest
Table 10.23: Lavipharm Over The Counter Division Therapeutic Areas of Interest
Table 10.24: Lavipharm Manufacturing Capacity of Pharmaceutical Products
Table 10.25: Noven Pharmaceuticals Timeline Events
Table 10.26: Noven Pharmaceuticals Current and In-Development Product Portfolio
Table 10.27 Nitto Denko Business Field and Major Products
Table 10.28 Teva Pharmaceuticals Business Highlights
Table 10.29 Teva Pharmaceuticals Key Strengths
Table 10.30 Teva Business Strategies
Table 10.31: Teva Pharmaceuticals Generics Business Facts
Table 10.32 Teva Pharmaceuticals Bestselling APIs
Table 10.33 Endo International Milestones
Table 10.34 Endo International Competitive Strengths
Table 10.35 Endo International Business Segments
Table 10.36 Endo International Acquisitions During FY2013
Table 10.37 Boehringer Business Segments and Therapeutic Areas of Interest
Table 10.38: Boehringer Ingelheim Branded Prescription Medicine Product Portfolio
Table 10.39: Boehringer Ingelheim Animal Health Care Product Portfolio
Table 10.40: Boehringer Ingelheim Consumer Health Care Product Portfolio
Table 10.41 3M Business Segments
Table 10.42: UCB Recent Partnerships
Table 10.43 Par Pharmaceutical Key Information
Table 10.44 Par Pharmaceutical Generic Product Portfolio
Table 10.45 Strativa Key Information
Table 10.46 Strativa Product Portfolio
Table 10.47 ParPharma Sterile Product Key Data
Table 10.48 ParPharma Sterile Product Portfolio
Table 11.1 Actavis Financial Highlights (Millions)
Table 11.2 Actavis Speciality Brands Pipeline Products
Table 11.3: Actelion Core Performance Figures FY2012-FY2013
Table 11.4: Actelion Employee Number by Department
Table 11.5: Actelion Product Portfolio by Therapeutic Area
Table 11.6: GlaxoSmithKline Financial Review FY2013
Table 11.7: GlaxoSmithKline Pharmaceuticals Sales by Therapeutic Area FY2013
Table 11.8: GlaxoSmithKline Vaccine Sales by Therapeutic Area FY2013
Table 11.9: GlaxoSmithKline Pharmaceuticals & Vaccines Sales Facts by Region FY2013
Table 11.10: GlaxoSmithKline Consumer Healthcare Sales by Therapeutic Area FY2013
Table 11.11: GlaxoSmithKline Pharmaceutical & Vaccine Turnover by Geographic Area FY2013
Table 11.12 GlaxoSmithKline Core R&D Expenditure FY2013
Table 11.13: GlaxoSmithKline Late Stage Pipeline Products
Table 11.14: ViiV Healthcare Top Therapeutic Agents FY2013
Table 11.15: Bayer Top Therapeutic Agents with High Potential FY2013
Table 11.16: Bayer Sales by Geographical Region FY2012-FY2013
Table 11.17: Bayer Top Pharmaceutical Products by Global Sales, FY2012-FY2013
Table 11.18: Bayer R&D Expenditure by Geographical Region FY2012-FY2013
Table 11.19: Top Selling Novartis Products FY2013 Globally
Table 11.20: Top Twenty Novartis Products FY2013 (by Sales) Globally
Table 11.21: Johnson & Johnson Top Performing Pharmaceutical Therapeutics FY2013
Table 11.22: Johnson & Johnson Top Performing New Pharmaceutical Therapeutics FY2013
Table 11.23: Nitto Dento Financial Highlights FY2013
Table 11.24: Teva Pharmaceuticals Financial Figures FY2010-FY2013
Table 11.25 Teva Pharmaceuticals Generic Medicine Revenues
Table 11.26: Teva Pharmaceuticals Generic Medicines Launched in 2013
Table 11.27 Teva Pharmaceuticals Specialty Medicines Revenue Breakdown (US$ Millions) 2011-2013
Table 11.28 Teva Pharmaceuticals Comparison of Specialty Product Sales FY2012 & 2011
Table 11.29: Teva Pharmaceuticals Selected Speciality Product Pipeline in Clinical Development
Table 11.30: Teva Pharmaceuticals New Therapeutic Entity (NTE) Products
Table 11.31: Teva Pharmaceuticals Revenues from Over the Counter (OTC) Products
Table 11.32 Endo International Top Selling Products per Business Segment
Table 11.33 Endo International Select Products From Qualitest Pharmaceuticals Portfolio
Table 11.34 Endo International Select Products From AMS Portfolio
Table 11.35: Boehringer Ingelheim Top Prescription Medicines FY2013
Table 11.36: Boehringer Ingelheim Top Consumer Health Products FY2013
Table 11.37: Boehringer Ingelheim R&D Highlights FY2013
Table 11.38: Boehringer Ingelheim Clinical Studies FY2013
Table 11.39: Boehringer Ingelheim R&D Animal Health
Table 11.40: 3M Sales Growth by Business Segment FY2013
Table 11.41: 3M Sales and Operating Income Detail by Business Segment FY2012-FY2013
Table 11.42: UCB Business Performance Highlights FY2013
Table 11.43: UCB North American Market Sales – Key Business Facts FY2013
Table 11.44: UCB European Market Sales – Key Business Facts FY2013
Table 11.45: UCB Japanese Market Sales – Key Business Facts FY2013
Table 11.46: UCB Emerging Market Sales – Key Business Facts FY2013
Table 11.47: UCB Research & Development Milestones
Table 11.48: UCB Product Pipeline
Table 12.1 Actavis Transdermal Delivery System Product Portfolio
Table 12.2: Actavis Pharma Product Portfolio
Table 12.3: GlaxoSmithKline Consumer Healthcare Products
Table 12.4: GlaxoSmithKline Niquitin/Nicoderm Transdermal Patch
Table 12.4: Bayer’s Product Portfolio by Therapeutic Area
Table 12.5: Bayer Women’s Healthcare Product Portfolio
Table 12.6: Top Global Cancer Therapeutics and Mechanism of Action– Novartis Portfolio
Table 12.7: Top Global Primary Care Therapeutics and Mechanism of Action– Novartis Portfolio
Table 12.8: Top Global Established Care Therapeutics and Mechanism of Action– Novartis Portfolio
Table 12.9: Top Global Specialty Care Therapeutics and Mechanism of Action– Novartis Portfolio
Table 12.10: Top Global Integrated Hospital Care Therapeutics and Mechanism of Action–Novartis Portfolio
Table 12.11: Top Transdermal drug Delivery Products: Novartis
Table 12.12: Janssen Pharmaceuticals Full List of Therapeutic Products
Table 12.13: Noven Pharmaceuticals Transdermal Drug Delivery Product Portfolio
Table 12.14: Teva Pharmaceuticals Speciality Products
Table 12.15: Endo International Product Portfolio
Table 12.16: Teikoku Transdermal Product Portfolio
Table 12.17: 3M Drug Delivery System Product Portfolio
Table 12.18: UCB NeuPro Transdermal Patch Details
Table 12.19: UCB’s Neupro Ti meline 2006-2013
Table 13.1: Technical Transdermal Product Challenges
Table 13.2: Technical Challenges of Generic Transdermals
Table 13.3: Technical Transdermal Product Development Challenges

List of Figures

Figure 2.1 Anatomy of the Stratum Corneum
Figure 2.2 Intracellular Pathways Through the Stratum Corneum
Figure 2.3 Fick’s Law of Diffusion
Figure 2.4 Transdermal Iontophoresis Delivery Pathway: A Sumatriptan Iontophoretic Transdermal System for the Acute Treatment of Migraine
Figure 3.1 Static Franz Diffusion Cell
Figure 3.2: Side-Bi-Side Cells
Figure 4.1 Different forms of Microemulsion
Figure 4.2 Multi-Compart mental Biphasix™ System
Figure 4.3 Possible Mechanisms of Action of Liposomes as Skin Drug Delivery Systems
Figure 4.4 Transdermal Patch Composition
Figure 4.5: Single-Layer Drug-in-Adhesive Transdermal Patch
Figure 4.6: Multi-Layer Drug-in-Adhesive Transdermal Patch
Figure 4.7 Reservoir Transdermal Drug Delivery Patch
Figure 4.8 Matrix Transdermal Drug Delivery Patch
Figure 4.9 The Metered Dose Transdermal System
Figure 4.10 Laser Ablation of Skin for Transdermal Drug Delivery
Figure 4.11 Microelectromechanical Systems (MEMS) in Transdermal Drug Delivery
Figure 4.12 Solid, Coated, Dissolving and Hollow Microneedles
Figure 4.13 AdminPatch Microneedle Array
Figure 4.14 MicroCor Microneedle Array
Figure 4.15 Microstructured Transdermal Systems
Figure 4.16 Zosanos Reusable Microflux Transdermal Microprojection Delivery System
Figure 4.17 DebioJect Microneedle Device
Figure 4.18 Transdermal Drug Delivery System by ZP Patch Technology
Figure 4.19 Injection vs Jet Injection
Figure 5.1 InoCyte Microinjectors
Figure 6.1 Agile Therapeutic Twirla Patch
Figure 6.2 The Endocrinology of Spermatogenesis and Male Hormonal Contraception
Figure 6.3 V-Go Insulin Delivery Device
Figure 6.4 Selective Serotonin-Reuptake Inhibitor (SSRI) Mode of Action
Figure 6.5 Ionsys Patch by ALZA Corp
Figure 6.6 DermaVir Transdermal Immunisation
Figure 7.1 Viral Gene Therapy Using an Adenovirus Vector
Figure 7.2 Preventing Protein Translation Using Antisense
Figure 8.1 Delivery of DNA Vaccine with in vivo Electroporation Enhances Cellular Immune Responses
Figure 8.2 Devices for Plasmid DNA Delivery
Figure 9.1: Global Drug Delivery System Historical Market ($ Billions) and CAGR 2010-2014
Figure 9.2: Global Drug Delivery System Market Forecast ($ Billions) and CAGR 2014-2020
Figure 9.3: Geographical Breakdown of Global Drug Delivery Market – USA, Europe, Asia, RoW 2014
Figure 9.4: Geographical Breakdown of Global Drug Delivery Market – USA, Europe, Asia, RoW 2017
Figure 9.5: USA Drug Delivery System Market Historical Figures 2010-2014
Figure 9.6: USA Drug Delivery System Market Forecast 2014-2020
Figure 9.7: Europe Drug Delivery Market Historic Worth 2010-2014
Figure 9.8: Europe Drug Delivery Market Forecast 2014-2020
Figure 9.9: The Advanced Global Drug Delivery – (Transdermal, Targeted, Transmucosal, Prodrugs, Sustained-Release, Intra-Uterine Device & Implant) Landscape 2007-2014
Figure 9.10: The Global Transdermal Drug Delivery Market 2010-2014
Figure 9.11: The Global Transdermal Drug Delivery Market 2014-2018
Figure 9.12: Transdermal Drugs (Number) in Pre-Clinical and Clinical Trials, Discontinued/Suspended and on the Global Market
Figure 9.13: Top Seven Transdermal Drug Products By Sales
Figure 9.14: Number of Premature Death Caused by Smoking Tobacco 2014-2030
Figure 9.15: Market Share of Smoking Cessation Therapeutics 2011-2016
Figure 9.16: Neuropathic Pain Market Worth (US, UK, France, Germany, Japan, Spain and Italy) 2010-2014
Figure 9.17: Neuropathic Pain Market Worth (US, UK, France, Germany, Japan, Spain and Italy) 2014-2020
Figure 9.18: Leading Therapeutics by Sales within the Neuropathic Pain Market 2014-2020
Figure 9.19: Global Generics Market Value 2012-2018
Figure 9.20: Number of US Patent Expirations by Oral and Differentiated Generics 2011-2019
Figure 9.21: Duragesic (Fentanyl Transdermal System) Sales 2002-2012
Figure 9.22: Comparison of Duragesic Sales to Mylan and Actavis Fentanyl Generic Transdermal
Figure 9.23: Endo Health Solutions – Lidoderm Net Sales 2011-2013
Figure 9.24: Endo Pharma Solutions Lidocaine Percentage of Total Business Revenue 2011-2014
Figure 9.25: Women’s Health Market Worth 2014-2018
Figure 10.1: Business Units of Novartis
Figure 11.1: Actavis Sales By Geographic Region, FY2013
Figure 11.2: Actavis Sales by Therapeutic Area FY2013
Figure 11.3: Actavis Sales by Specialty Segment FY2012
Figure 11.4 Actelion Sales by FY2011-FY2013
Figure 11.5 Actelion Core Earnings FY2011-FY2013
Figure 11.6 Actelion Core R&D Expenditure 2011-2013
Figure 11.7 GSK Turnover by Business FY2013
Figure 11.8 GSK Turnover by Region FY2013
Figure 11.9 GSK Turnover by Segment FY2013
Figure 11.10 GlaxoSmithKline Pharmaceutical Research & Development Investment FY2013
Figure 11.11: Bayer Revenue Generated From Sales FY2012-FY2013
Figure 11.12: Bayer Net Income FY2012-FY2013
Figure 11.13: Bayer Earnings Before Financial Result and Taxes FY2012-FY2013
Figure 11.14: Bayer Revenue Generated From Health Care, Crop Care and Material Science Divisions, FY2012-FY2013
Figure 11.15: Bayer Percentage Sales by Business Division FY2013
Figure 11.16: Bayer Sales by Geographical Region FY2012-FY2013
Figure 11.17: Bayer Top Five Pharmaceutical Drug Revenue Generators FY2013
Figure 11.18: Bayer Research and Development Expenditure FY2012-FY2013
Figure 11.19: Bayer R&D Expenditure by Geographical Region FY2012-FY2013
Figure 11.20: Mylan Pharmaceuticals Total Revenue FY2012-FY2013
Figure 11.21: Mylan Pharmaceuticals Consolidated Gross Profit FY2012-FY2013
Figure 11.22: Mylan Pharmaceuticals Global & Country Level Approvals & Submissions FY2013
Figure 11.23: Mylan Pharmaceuticals Number of Country Level Product Submissions 2013
Figure 11.24: Mylan Pharmaceuticals Country Level Product Approvals 2013, Globally
Figure 11.25: Mylan Pharmaceuticals R&D Spending 2011-Present
Figure 11.26: Mylan Pharmaceutical Percentage Consolidated Net Revenue Share of Major Customers, 2011-2013
Figure 11.27: Novartis Net Sales ($ Billions) FY2012-FY2013
Figure 11.28: Novartis Net Sales ($ Billions) by Geography, FY2013
Figure 11.29: Novartis Percentage Net Sales by Geography, FY2013
Figure 11.30: Novartis R&D Expenditure by Business Area FY2013
Figure 11.31: Novartis Exelon/Exelon Patch Net Sales by Geography FY2013
Figure 11.32: Novartis Pipeline Portfolio 2014-2018 and Beyond
Figure 11.33: Johnson & Johnson Total Sales by Business Division: Pharmaceuticals, Medical Devices & Diagnostics, Consumer Health FY2013
Figure 11.34: Johnson & Johnson Distribution of Sales – Pharmaceuticals, Medical Devices & Diagnostics, Consumer Health FY2013
Figure 11.35: Johnson & Johnson Pharmaceutical Segment Sales FY2013
Figure 11.36: Johnson & Johnson Medical Device and Diagnostic Sales FY2013
Figure 11.37: Johnson & Johnson Consumer Healthcare Sales FY2013
Figure 11.38: Shire Global Revenue and Sales FY2013
Figure 11.39: Shire Sales by Geography FY2013
Figure 11.40: Nitto Dento Sales Revenue (Yen, millions) FY2008-FY2013
Figure 11.41: Nitto Dento Net Income (Yen millions) FY2008-FY2013
Figure 11.42: Nitto Dento Geographical Breakdown of Sales FY2013
Figure 11.43: Teva Pharmaceuticals Global Gross Profit FY2006-FY2013
Figure 11.44: Teva Pharmaceuticals Global Net Income FY2006-FY2013
Figure 11.45: Endo International Revenue by Business Segment (US $ Millions) FY2013
Figure 11.46: Endo International Top Selling Product Revenue FY2013
Figure 11.47: Endo International Global Lidoderm Sales FY2011-FY2013
Figure 11.48: Endo International Global Fortesa Sales FY2011-FY2013
Figure 11.49: Boehringer Ingelheim Sales by Business Segment FY2013
Figure 11.50: Boehringer Ingelheim Sales by Geographic Region FY2013
Figure 11.51: 3M Net Sales by Geographical Region FY2013
Figure 11.52: 3M Research & Development Spend FY2011-FY2013
Figure 11.53: UCB Revenue & Earnings Before Tax (€ Millions) FY2009-FY2013
Figure 11.54: UCB Geographical Sales FY2013
Figure 11.55: UCB Key Product Sales FY2013
Figure 11.56: ParPharm Top Generic Products by Revenue FY2013
Figure 12.1 Niquitin Transdermal System Patch Technology

Note: Product cover images may vary from those shown
3 of 6


4 of 6


  • 3M
  • Ascend Therapeutics
  • Endo International
  • Janssen Pharmaceuticals
  • Novartis
  • ProStrakan
  • MORE
“GLOBAL & USA TRANSDERMAL DRUG DELIVERY MARKET TO 2020: Strategic Analysis, Technologies, Competitor Profiles, Financial Evaluation, Product Pipeline Assessment and SWOT Investigation” is a dedicated report on the transdermal drug delivery industry and its impact on the USA and global markets.

This comprehensive report tackles problems that this vertical growing market faces and evaluates saturated sub-markets. A detailed outlay of its major players is performed including business strategy and future development analysis, merger and acquisition tactics, current product and pipeline entry evaluation and a detailed section on each player’s financial situation. This analysis determines the unmet needs of the transdermal drug delivery industry and specific niche areas of market entry.

The transdermal drug delivery market has substantial associations within the smoking cessation market, analgesics/pain market, generics market, neuropathic pain market and also the women’s health market. In the future it will enter the vaccine and gene therapy markets. Transdermal drug delivery is a complex area that has many driving factors including the unmet need for non-invasive drug delivery systems for pediatric, geriatric and dementia patients.

This report describes the current technologies that are propelling the market space and emerging trials and pipeline agents that will make a significant impact on the industry. It examines the current transdermal delivery systems and how generic competition is allowing penetration of new players in the market and saturation of niche areas.

Financial figures of the drug delivery market and the transdermal drug delivery space are revealed in this report. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry. The study also provides a comprehensive financial, business strategy and product review of key players in the transdermal drug delivery industry. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.

In summary, the transdermal drug delivery market has huge opportunities for growth in the areas of dementia (Alzheimer’s & Parkinson’s Disease), generics, paediatrics and geriatrics. Currently the USA is the most prominent market place, followed by Europe, Asia and Emerging Markets. This report will reveal in-depth analysis of the industry and provide cutting-edge intelligence on the current and future spaces it will penetrate.
In 2014, the global drug delivery market (DDM) was worth just under $x billion, a significant jump from $x billion in 2010. The market grew steadily within this time period with a compound annual growth interest of x%. By the end of 2016, it is expected to be worth over $x billion, and make gains to over $x billion by 2020.

Today the US market holds just over x% share, and within the next five years Asian and Emerging market spaces will increase in size. By 2020, the Asian drug delivery market will surge past x%, compared to over x% in Europe. The US total drug delivery market will continue to maintain its x% share by 2020.

Within the total drug delivery market exists the advanced DDM, which is further segmented into the following niche areas:
- Transdermal
- Transmucosal
- Targeted
- Sustained-released agents
- Prodrugs
- Implants
- Intrauterine devices
- Oral

Targeted drug delivery is the most significant player within this space, and generated $x billion globally in 2014. Currently, targeted drug delivery systems are indicated in specific cancers, diabetes, tuberculosis and also cardiovascular disorders. These ‘nanocarriers’ are forecast to propel the advanced drug delivery space by an estimated $x million by 2021.

Note: Product cover images may vary from those shown
5 of 6
- Actavis
- Actelion
- GlaxoSmithKline
- Bayer
- Mylan Pharmaceuticals
- Novartis
- Upsher-Smith
- Ascend Therapeutics
- AMAG Pharmaceuticals (Lumara Health, KV Pharm/Ther-Rx Corp)
- Janssen Pharmaceuticals
- Noven Pharmaceuticals
- ProStrakan
- Shire
- Hercon Pharmaceutical
- Kremers Urban Pharmaceuticals
- Nitto Denko
- Teva Pharmaceutical Industries
- Endo International
- Teikoku USA
- Boehringer Ingelheim
- 3M
- ParPharm

Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown